<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759276</url>
  </required_header>
  <id_info>
    <org_study_id>RiodeJaneiro_StateUniversity</org_study_id>
    <secondary_id>BIOVASC-UERJ</secondary_id>
    <nct_id>NCT02759276</nct_id>
  </id_info>
  <brief_title>Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure</brief_title>
  <acronym>MICRORAH</acronym>
  <official_title>Inflammatory Biomarkers and Endothelial Function Assessed by Venous Occlusion Plethysmography and Nailfold Videocapillaroscopy in Patients With Resistant Hypertension, Stages 1 and 2 and Normotensive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Alexandre Bottino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rio de Janeiro State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and inflammatory
      biomarkers have been used to study endothelial function in patients with resistant
      hypertension, stages 1 and 2 hypertension and normotensive. This was a cross-sectional study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microcirculation determines peripheral resistance contributing to increased blood pressure.
      The nailfold videocapillaroscopy (NVC), Venous occlusion Plethysmography (VOP) and biomarkers
      can be used to evaluate the microcirculation in arterial hypertension (AH). The objective of
      this study is to analyze the behavior of serum inflammatory markers and study the
      microcirculation by nailfold videocapillaroscopy (NVC) and Venous Occlusion Plethysmography
      in patients with resistant hypertension (RH), with stages 1 and 2 hypertension (MMH ) and
      normotensive (CG). A cross-sectional study with 75 patients has been performed: 25 with
      resistant hypertension (RH), 25 with stages 1 and 2 hypertension (MMH) and 25 normotensive
      (CG). All underwent anamnesis, dosage serum markers and conducting NVC, VOP. Hypertensive
      patients without statin use and with controlled or uncontrolled blood pressure were also
      analyzed. For the statistical analysis were used: Kruskal -Wallis ANOVA, Dunn test and ANCOVA
      for correction of confusion factors such as age and BMI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure (mmHg)</measure>
    <time_frame>1 day</time_frame>
    <description>Hemodynamic Variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Capillary Density (FCD, number capillaries/mm2 )</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Afferent Capillary Diameter (micrometer)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apical Capillary Diameter (micrometer)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efferent Capillary Diameter (micrometer)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Velocity (mm/s)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Red Blood Cell Velocity (mm/s)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Maximum Red Blood Cell Velocity (s)</measure>
    <time_frame>1 day</time_frame>
    <description>Microcirculatory variable from Nailfold Videocapillaroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (cm)</measure>
    <time_frame>1 day</time_frame>
    <description>Anthropometrical Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference (cm)</measure>
    <time_frame>1 day</time_frame>
    <description>Anthropometrical Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist to Hip Ratio</measure>
    <time_frame>1 day</time_frame>
    <description>Anthropometrical Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (Kg/m2)</measure>
    <time_frame>1 day</time_frame>
    <description>Anthropometrical Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Forearm Blood Flow during reactive Hyperemia</measure>
    <time_frame>1 day</time_frame>
    <description>Vascular Reactivity Variables from Venous Occlusion Plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Forearm Blood Flow after sublingual nitroglycerine</measure>
    <time_frame>1 day</time_frame>
    <description>Vascular Reactivity Variables from Venous Occlusion Plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Cell Adhesion Molecule (VCAM, ng/dl)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intercellular Adhesion Molecule (ICAM, ng/dl)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin (ng/dl)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelin (pg/dl)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein (CRP, mg/dl)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Resistant Hypertension (RH)</arm_group_label>
    <description>uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stages 1 and 2 Hypertension (MMH)</arm_group_label>
    <description>According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive (CG)</arm_group_label>
    <description>Blood Pressure &lt;140/90 mmHg and without comorbidities.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        First Day: Full clinical examination was performed, including measurements of at-rest blood
        pressure, weight and height in order to calculate Body Mass Index (BMI), waist and hip
        measurements.

        Second Day: drawing blood for laboratory analyses, Nailfold Videocapillaroscopy and Venous
        Occlusion Plethysmography.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of controlled High Blood Pressure stages 1 and 2 (blood pressure
             levels from 140/90 mmHg to 179/109 mmHg) .

          -  Resistant Hypertension (uncontrolled hypertension, with values ≥140/90 mmHg, using
             three or more antihypertensive drugs of different classes, including a diuretic, or
             controlled hypertension with four or more drugs).

          -  Normal Blood Pressure.

        Exclusion Criteria:

          -  Diabetes Mellitus, Types 1 or 2.

          -  Heart Failure.

          -  Myocardial infarction or stroke with less than three months of the event.

          -  Chronic kidney disease.

          -  Use of hormonal or non-hormonal anti-inflammatory drugs.

          -  Recent trauma (less than three months).

          -  Autoimmune diseases.

          -  Infectious processes in activity.

          -  Neoplasia.

          -  Aspirin use (anti-inflammatory dose).

          -  Obesity grade III (Body Mass Index&gt;40 kg/m2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rio de Janeiro State University</investigator_affiliation>
    <investigator_full_name>Daniel Alexandre Bottino</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>Nailfold Videocapillaroscopy</keyword>
  <keyword>Venous Occlusion Plethysmography</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Inflammatory Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

